Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC exosomes for uterine endometrial injury
ChiCTR1800018327Phase 2Not yet recruiting
- Sponsor
- Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
- Start
- Oct 2018
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mesenchymal stem cell exosomes in Uterine rupture (UR), sponsored by Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine. Primary endpoints: Endometrial thickness, Endometrial receptivity and 1 more. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
Uterine rupture (UR)
Beyond the preview
Go deeper on ChiCTR1800018327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018327.